Search Results
Nov 25, 2025, 16:05 ET Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Nov 19, 2025, 02:55 ET Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Nov 06, 2025, 07:05 ET Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Nov 04, 2025, 16:05 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Oct 29, 2025, 16:05 ET Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Oct 22, 2025, 16:05 ET Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Oct 21, 2025, 07:05 ET Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Oct 15, 2025, 16:05 ET Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Oct 08, 2025, 08:08 ET American Staffing Association Names 2026 Board Officers and Directors
Goodwin, Exact Staff Inc.; Laura MacNeel, Aya Healthcare; Robin Mee, MeeDerby; Ranjini Poddar, Artech LLC; Mark Toth, CSP, ManpowerGroup; Steve Wehn, AMN Healthcare; and DeLibra Wesley, National Recruiting Consultants. "The staffing industry is transforming the future of hiring,"
More news about: American Staffing Association
Sep 30, 2025, 11:00 ET American Staffing Association Honors Top Social Responsibility Programs in Staffing and Recruiting
"Employee Volunteer Programs" Honorable Mentions AMN Healthcare, "Resiliency of the American Workforce"Aquent, "Achieving Carbon Negative" Staffing
More news about: American Staffing Association
Sep 04, 2025, 16:15 ET MAAG Group Launches PEARLO CS, a Compact Pelletizing Solution
Pulverizing Systems, Recycling Systems and Measurement & Control Systems divisions consolidate the many years of experience and in-depth know-how of the AMN, AUTOMATIK, ETTLINGER, GALA, MAAG, REDUCTION, SCHEER, SIKORA, WITTE and XANTEC product brands. The MAAG Group currently employs over 1,900 people at
More news about: Dover
Aug 28, 2025, 16:30 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Aug 19, 2025, 07:08 ET Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Aug 07, 2025, 10:07 ET O.R. Staffing Solutions Announces New CEO & Board of Directors
President, AHS Staffing (AHS), part of AHSG, where he oversaw its nationwide nurse and allied business. Prior to AHS, Brent spent 18 years at AMN Healthcare (NYSE: AMN) and was Divisional Vice President overseeing its hospitalists and emergency medicine divisions. Mark and Jerick, experienced healthcare staffing
More news about: Argosy Healthcare Partners
Jul 30, 2025, 17:46 ET THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight
developed for X-linked adrenoleukodystrophy (X‑ALD), particularly the adrenomyeloneuropathy (AMN) form, and has received orphan drug designation from the US FDA. In a placebo-controlled Phase Ib study in adult males with AMN, VK0214 was well-tolerated with once-daily dosing over 28 days and produced significant
More news about: DelveInsight Business Research, LLP
Jul 23, 2025, 16:05 ET Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 demonstrated a promising safety profile and was well-tolerated, while driving significant reductions in plasma levels of very
More news about: Viking Therapeutics, Inc.
Jul 16, 2025, 16:05 ET Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.
Jul 02, 2025, 08:30 ET symplr Acquires AMN Healthcare's Smart Square Scheduling Software, Enhancing AI-Driven Workforce Optimization for Health Systems
Charlesbank Capital Partners LLC (together with its affiliates, "Charlesbank"), has acquired the Smart Square® scheduling software from AMN Healthcare (NYSE: AMN).
More news about: symplr
Jun 25, 2025, 07:03 ET Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids
More news about: Viking Therapeutics, Inc.